GLP-2 (T)

$59.00

Weight

Quantity

Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials. Its ~5‑day half‑life enables convenient once‑weekly administration,
Observations from clinical trials and published literature.

Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.

Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses).

Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.

Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence.

Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Complementary strategies for best outcomes.

Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.

Prioritize protein to preserve lean mass during weight loss.

Combine resistance training and aerobic activity to support metabolic health.

Stay hydrated, especially given potential gastrointestinal effects.

Prioritize sleep and stress management to support adherence and recovery.

GLP-2 (T)

How This Works

Potential Benefits & Side Effects

Lifestyle Factors